HealthRX.com · Printable lab tracker
After-ibutamoren record: the results your clinician orders, swelling, hand numbness and appetite
Keeps the exposure history, any results a clinician orders and the symptoms this page lists in one dated record after stopping MK-677, without assuming a fixed recovery timetable.
Exposure history
Product name and seller, as labeled
Date first taken and date last taken
Other growth-hormone-related products used in the same period
Why you stopped
Results from before you started, if you have them
Results your clinician orders
Copy the units and the lab's reference range exactly as printed.
| Date drawn | Test (for example IGF-1, fasting glucose, HbA1c) | Result and units | Lab reference range | Clinician comment |
|---|---|---|---|---|
Symptoms after stopping
| Date | Appetite | Swelling in feet, ankles or legs | Numbness or tingling in the hands | Breathlessness or quick weight gain | Sleep |
|---|---|---|---|---|---|
What the ibutamoren trials can tell you
- In a 2-year trial in healthy adults aged 60 to 81, IGF-I was back at pretreatment levels 1 month after switching to placebo, and 3 and 6 months after the study ended.[1]
- In the same trial, the year-1 changes reversed in people switched to placebo for year 2.[1]
- In a placebo-controlled trial of 24 obese men aged 18 to 50, half given ibutamoren for 8 weeks, fasting glucose and insulin did not change, but a glucose tolerance test showed impaired glucose handling at 2 and 8 weeks, so a normal fasting value alone may not tell the whole story.[2]
- A trial in older adults recovering from hip fracture was stopped early because of a congestive heart failure signal.[3]
- FDA lists ibutamoren mesylate among bulk substances that may present significant safety risks (for outsourcing facilities since December 29, 2022 and for 503A pharmacies since September 29, 2023), citing potential congestive heart failure in certain patients.[4]
For the clinician reviewing this record
- Which tests, if any, do you want after I stop, and when?
- Is a glucose tolerance test or HbA1c more useful for me than a single fasting glucose?
- Which signs of fluid build-up should make me call you rather than wait?
- Could hand numbness or swelling be related, and how long should I watch it?
- Should my other prescribers be told that I used ibutamoren?
Sources for the facts on this sheet
- Nass R, Pezzoli SS, Oliveri MC, Patrie JT, Harrell FE Jr, Clasey JL, Heymsfield SB, Bach MA, Vance ML, Thorner MO. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med 2008. PMID 18981485. https://pubmed.ncbi.nlm.nih.gov/18981485/
- Svensson J, Lönn L, Jansson JO, Murphy G, Wyss D, Krupa D, Cerchio K, Polvino W, Gertz B, Boseaus I, Sjöström L, Bengtsson BA. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J Clin Endocrinol Metab 1998. PMID 9467542. https://pubmed.ncbi.nlm.nih.gov/9467542/
- Adunsky A, Chandler J, Heyden N, Lutkiewicz J, Scott BB, Berd Y, Liu N, Papanicolaou DA. MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. Arch Gerontol Geriatr 2011. PMID 21067829. https://pubmed.ncbi.nlm.nih.gov/21067829/
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Accessed 2026-10-19. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
This sheet records information for a conversation with your prescriber or pharmacist. It does not replace their instructions or the medication's prescribing information.